Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Melanoma 14Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Myelodysplastic Syndromes 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Basal Cell 3Burkitt Lymphoma 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Cyclophosphamide 77Paclitaxel 48Trastuzumab 40Tamoxifen 39Doxorubicin 37Docetaxel 35Radiotherapy 32Fluorouracil 26Chemotherapy, Adjuvant 26Taxes 23Epirubicin 22Carboplatin 22Filgrastim 21Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 19Neoadjuvant Therapy 18aldesleukin 16Peripheral Blood Stem Cell Transplantation 16Bevacizumab 13Lapatinib 12CMF regimen 12Anastrozole 12exemestane 11Goserelin 11Capecitabine 11Biopsy 11veliparib 10sargramostim 10fludarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms × CTLA-4 Antigen × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
BreastCNSGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Teratoma, Testicular, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Neuroblastoma, Teratoma, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡